Results 201 to 210 of about 13,472,146 (356)
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha +10 more
wiley +1 more source
On the response of the peeled-off Gafchromic EBT2 film to argon plasma jet. [PDF]
El-Naggar HI +7 more
europepmc +1 more source
Variational energy functionals of the Green function and of the density tested on molecules
N. Dahlen, R. Leeuwen, U. Barth
semanticscholar +1 more source
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou +5 more
wiley +1 more source
ACOX1 gain-of-function post-mortem neuropathology is distinct from ACOX1 loss-of-function: case report and literature review. [PDF]
Hubler Z +9 more
europepmc +1 more source
Elastodynamic 2D Green function retrieval from cross‐correlation: Canonical inclusion problem
F. Sánchez-Sesma +3 more
semanticscholar +1 more source
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source

